Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Fecha de publicación: 01/07/2022 Fecha Ahead of Print: 26/04/2022

Autores de IIS La Fe

Antonio Conde Moreno

Autor

Participantes ajenos a IIS La Fe

Achard V
Jaccard M
Vanhoutte F
Siva S
Heikkilä R
Dirix P
Liefhooghe N
Otte FX
Gomez-Iturriaga A
Berghen C
Shelan M
Campos FL
Papachristofilou A
Guckenberger M
Meersschout S
Putora PM
Zwahlen D
Couñago F
Scorsetti M
Eito C
Barrado M
Zapatero A
Muto P
Van De Voorde L
Lamanna G
Koutsouvelis N
Dipasquale G
Ost P
Zilli T

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

PURPOSE: Aim of this study is to report the results of the radiotherapy quality assurance program of the PEACE V-STORM randomized phase II trial for pelvic nodal oligorecurrent prostate cancer (PCa). MATERIAL AND METHODS: A benchmark case (BC) consisting of a postoperative case with 2 nodal recurrences was used for both stereotactic body radiotherapy (SBRT, 30 Gy/3 fx) and whole pelvic radiotherapy (WPRT, 45 Gy/25 fx + SIB boost to 65 Gy). RESULTS: BC of 24 centers were analyzed. The overall grading for delineation variation of the 1st BC was rated as 'UV' (Unacceptable Variation) or 'AV' (Acceptable Variation) for 1 and 7 centers for SBRT (33%), and 3 and 8 centers for WPRT (46%), respectively. An inadequate upper limit of the WPRT CTV (n = 2), a missing delineation of the prostate bed (n = 1), and a missing nodal target volume (n = 1 for SBRT and WPRT) constituted the observed 'UV'. With the 2nd BC (n = 11), the overall delineation review showed 2 and 8 'AV' for SBRT and WPRT, respectively, with no 'UV'. For the plan review of the 2nd BC, all treatment plans were per protocol for WPRT. SBRT plans showed variability in dose normalization (Median D(90%) = 30.1 Gy, range 22.9-33.2 Gy and 30.6 Gy, range 26.8-34.2 Gy for nodes 1 and 2 respectively). CONCLUSIONS: Up to 46% of protocol deviations were observed in delineation of WPRT for nodal oligorecurrent PCa, while dosimetric results of SBRT showed the greatest disparities between centers. Repeated BC resulted in an improved adherence to the protocol, translating in an overall acceptable contouring and planning compliance rate among participating centers.

Datos de la publicación

ISSN/ISSNe:: 0167-8140, 1879-0887
Tipo:: Article
Páginas:: 1-9
DOI:: 10.1016/j.radonc.2022.04.020
Factor de Impacto:: 1,946 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Achard V:: Department of Radiation Oncology, Geneva University Hospital, Switzerland
Jaccard M:: Department of Radiation Oncology, Geneva University Hospital, Switzerland
Vanhoutte F:: Department of Radiation Oncology, Ghent University Hospital, Belgium
Siva S:: EJ Whitten Foundation Prostate Cancer Research Centre, Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
Heikkilä R:: Department of Oncology, Oslo University Hospital, Norway
Dirix P:: Department of Radiation Oncology, Iridium Kankernetwerk, Antwerp, Belgium

University of Antwerp, Faculty of Medicine and Health Sciences, Belgium
Liefhooghe N:: Department of Radiation oncology, AZ Groeninge, Kortrijk, Belgium
Otte FX:: Department of Radiation Oncology, Jules Bordet Institute and Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Belgium
Gomez-Iturriaga A:: Department of Radiation Oncology, Cruces University Hospital (Biocruces Health Research Institute), Barakaldo, Spain
Berghen C:: Department of Radiation Oncology, University Hospitals Leuven, Belgium
Shelan M:: Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland
Conde-Moreno A:: Department of Radiation Oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain
Campos FL:: Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Papachristofilou A:: Department of Radiotherapy and Radiation Oncology, University Hospital Basel, Switzerland
Guckenberger M:: Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Switzerland
Meersschout S:: Department of Radiation Oncology, AZ-St Jan-Brugge, Belgium
Putora PM:: Department of Radiation Oncology, Kantonspital St. Gallen, Switzerland
Zwahlen D:: Department of Radiation Oncology, Kantonspital Winterthur, Switzerland
Couñago F:: Department of Radiation Oncology, University Hospital Quironsalud, Universidad Europea de Madrid, Spain
Scorsetti M:: Department of Radiation Oncology, Humanitas Clinical and Research Hospital, IRCSS, Radiotherapy and Radiosurgery Department, Rozzano, Italy
Eito C:: Department of Radiation Oncology, Instituto Oncólogico Clinica Universitaria IMQ, Bilbao, Spain
Barrado M:: Department of Radiation Oncology, Complejo Hospitalario de Navarra, Spain
Zapatero A:: Department of Radiation Oncology, University Hospital La Princesa, Madrid, Spain
Muto P:: Department of Radiation Oncology, Napoli Istituto Nazionale Tumori IRCCS Fondazione Pascale, Italy
Van De Voorde L:: Department of Radiation Oncology, AZ St-Lucas Ghent, Belgium
Lamanna G:: Department of Radiation Oncology, Geneva University Hospital, Switzerland
Koutsouvelis N:: Department of Radiation Oncology, Geneva University Hospital, Switzerland
Dipasquale G:: Department of Radiation Oncology, Geneva University Hospital, Switzerland
Ost P:: Department of Radiation Oncology, Ghent University Hospital, Belgium

Department of Human Structure and Repair, Ghent University, Belgium
Zilli T:: Department of Radiation Oncology, Geneva University Hospital, Switzerland